论文部分内容阅读
目的:探讨妊娠期肝内胆汁淤积综合症患者的治疗过程对母婴预后的影响。方法:将2011年1月~2014年1月来我院就诊的136例妊娠期肝内胆汁淤积症患者进行无差异分组。对照组68例为不接受治疗和监护或未曾发现病情症状的患者。实验组68例患者采用地塞米松、熊去氧胆酸等药物进行联合用药,对患者在孕期的各项指标进行检测。结果:对照组患者不良反应率远高于实验组,其中围产儿死亡率为17.6%,早产发生率为30.8%,羊水感染率为25%。结论:采用地塞米松和熊去氧胆酸联合治疗妊娠期肝内胆汁淤积综合症的临床效果比不治疗组有明显提升,具备临床推广价值。
Objective: To investigate the influence of the course of treatment on the prognosis of maternal and infant in patients with intrahepatic cholestasis syndrome during pregnancy. METHODS: 136 patients with intrahepatic cholestasis of pregnancy who came to our hospital from January 2011 to January 2014 were randomly divided into groups. Sixty-eight patients in the control group were untreated and monitored or had no symptoms. The experimental group of 68 patients with dexamethasone, ursodeoxycholic acid and other drugs for combination therapy, the indicators of patients during pregnancy were detected. Results: The adverse reaction rate of the control group was much higher than that of the experimental group. The perinatal mortality rate was 17.6%, the preterm birth rate was 30.8% and the amniotic fluid infection rate was 25%. Conclusion: The combination of dexamethasone and ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy in clinical efficacy than the untreated group was significantly improved, with clinical value.